255 related articles for article (PubMed ID: 33648930)
21. RELA/NEAT1/miR-302a-3p/RELA feedback loop modulates pancreatic ductal adenocarcinoma cell proliferation and migration.
Luo Z; Yi ZJ; Ou ZL; Han T; Wan T; Tang YC; Wang ZC; Huang FZ
J Cell Physiol; 2019 Apr; 234(4):3583-3597. PubMed ID: 30362505
[TBL] [Abstract][Full Text] [Related]
22. Linc00511 acts as a competing endogenous RNA to regulate VEGFA expression through sponging hsa-miR-29b-3p in pancreatic ductal adenocarcinoma.
Zhao X; Liu Y; Li Z; Zheng S; Wang Z; Li W; Bi Z; Li L; Jiang Y; Luo Y; Lin Q; Fu Z; Rufu C
J Cell Mol Med; 2018 Jan; 22(1):655-667. PubMed ID: 28984028
[TBL] [Abstract][Full Text] [Related]
23. Long noncoding RNA Linc00337 functions as an E2F1 co-activator and promotes cell proliferation in pancreatic ductal adenocarcinoma.
Wang H; Yu S; Peng H; Shu Y; Zhang W; Zhu Q; Wu Y; Xu Y; Yan J; Xiang H
J Exp Clin Cancer Res; 2020 Oct; 39(1):216. PubMed ID: 33054826
[TBL] [Abstract][Full Text] [Related]
24. Maintenance Therapy for ATM-Deficient Pancreatic Cancer by Multiple DNA Damage Response Interferences after Platinum-Based Chemotherapy.
Roger E; Gout J; Arnold F; Beutel AK; Müller M; Abaei A; Barth TFE; Rasche V; Seufferlein T; Perkhofer L; Kleger A
Cells; 2020 Sep; 9(9):. PubMed ID: 32948057
[TBL] [Abstract][Full Text] [Related]
25. Targeting CRABP-II overcomes pancreatic cancer drug resistance by reversing lipid raft cholesterol accumulation and AKT survival signaling.
Yu S; Wang L; Che D; Zhang M; Li M; Naito M; Xin W; Zhou L
J Exp Clin Cancer Res; 2022 Mar; 41(1):88. PubMed ID: 35260193
[TBL] [Abstract][Full Text] [Related]
26. The Clinical Significance of miR-34a in Pancreatic Ductal Carcinoma and Associated Molecular and Cellular Mechanisms.
Long LM; Zhan JK; Wang HQ; Li S; Chen YY; Liu YS
Pathobiology; 2017; 84(1):38-48. PubMed ID: 27458977
[TBL] [Abstract][Full Text] [Related]
27. Marker-free lineage tracing reveals an environment-instructed clonogenic hierarchy in pancreatic cancer.
Lodestijn SC; Miedema DM; Lenos KJ; Nijman LE; Belt SC; El Makrini K; Lecca MC; Waasdorp C; van den Bosch T; Bijlsma MF; Vermeulen L
Cell Rep; 2021 Oct; 37(3):109852. PubMed ID: 34686335
[TBL] [Abstract][Full Text] [Related]
28. SCNrank: spectral clustering for network-based ranking to reveal potential drug targets and its application in pancreatic ductal adenocarcinoma.
Liu E; Zhang ZZ; Cheng X; Liu X; Cheng L
BMC Med Genomics; 2020 Apr; 13(Suppl 5):50. PubMed ID: 32241274
[TBL] [Abstract][Full Text] [Related]
29. Upregulated circular RNA circ_0007534 indicates an unfavorable prognosis in pancreatic ductal adenocarcinoma and regulates cell proliferation, apoptosis, and invasion by sponging miR-625 and miR-892b.
Hao L; Rong W; Bai L; Cui H; Zhang S; Li Y; Chen D; Meng X
J Cell Biochem; 2019 Mar; 120(3):3780-3789. PubMed ID: 30382592
[TBL] [Abstract][Full Text] [Related]
30. EZH2 Regulates Pancreatic Cancer Subtype Identity and Tumor Progression via Transcriptional Repression of
Patil S; Steuber B; Kopp W; Kari V; Urbach L; Wang X; Küffer S; Bohnenberger H; Spyropoulou D; Zhang Z; Versemann L; Bösherz MS; Brunner M; Gaedcke J; Ströbel P; Zhang JS; Neesse A; Ellenrieder V; Singh SK; Johnsen SA; Hessmann E
Cancer Res; 2020 Nov; 80(21):4620-4632. PubMed ID: 32907838
[TBL] [Abstract][Full Text] [Related]
31. A pharmacogenomic analysis using L1000CDS
Choi EA; Choi YS; Lee EJ; Singh SR; Kim SC; Chang S
Cancer Lett; 2019 Nov; 465():82-93. PubMed ID: 31404615
[TBL] [Abstract][Full Text] [Related]
32. circNFIB1 inhibits lymphangiogenesis and lymphatic metastasis via the miR-486-5p/PIK3R1/VEGF-C axis in pancreatic cancer.
Kong Y; Li Y; Luo Y; Zhu J; Zheng H; Gao B; Guo X; Li Z; Chen R; Chen C
Mol Cancer; 2020 May; 19(1):82. PubMed ID: 32366257
[TBL] [Abstract][Full Text] [Related]
33. Circular RNA circBFAR promotes the progression of pancreatic ductal adenocarcinoma via the miR-34b-5p/MET/Akt axis.
Guo X; Zhou Q; Su D; Luo Y; Fu Z; Huang L; Li Z; Jiang D; Kong Y; Li Z; Chen R; Chen C
Mol Cancer; 2020 May; 19(1):83. PubMed ID: 32375768
[TBL] [Abstract][Full Text] [Related]
34. DHA-SBT-1214 Taxoid Nanoemulsion and Anti-PD-L1 Antibody Combination Therapy Enhances Antitumor Efficacy in a Syngeneic Pancreatic Adenocarcinoma Model.
Ahmad G; Mackenzie GG; Egan J; Amiji MM
Mol Cancer Ther; 2019 Nov; 18(11):1961-1972. PubMed ID: 31439714
[TBL] [Abstract][Full Text] [Related]
35. Macrophage-Derived Granulin Drives Resistance to Immune Checkpoint Inhibition in Metastatic Pancreatic Cancer.
Quaranta V; Rainer C; Nielsen SR; Raymant ML; Ahmed MS; Engle DD; Taylor A; Murray T; Campbell F; Palmer DH; Tuveson DA; Mielgo A; Schmid MC
Cancer Res; 2018 Aug; 78(15):4253-4269. PubMed ID: 29789416
[TBL] [Abstract][Full Text] [Related]
36. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
[TBL] [Abstract][Full Text] [Related]
37. Long non-coding RNA CERS6-AS1 facilitates the oncogenicity of pancreatic ductal adenocarcinoma by regulating the microRNA-15a-5p/FGFR1 axis.
Yun Z; Meng F; Li S; Zhang P
Aging (Albany NY); 2021 Feb; 13(4):6041-6054. PubMed ID: 33581689
[TBL] [Abstract][Full Text] [Related]
38. Nanotechnology-Based Strategy for Enhancing Therapeutic Efficacy in Pancreatic Cancer: Receptor-Targeted Drug Delivery by Somatostatin Analog.
Gu X; Majumder J; Taratula O; Kuzmov A; Garbuzenko O; Pogrebnyak N; Minko T
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791582
[TBL] [Abstract][Full Text] [Related]
39. Yin Yang-1 suppresses pancreatic ductal adenocarcinoma cell proliferation and tumor growth by regulating SOX2OT-SOX2 axis.
Zhang JJ; Zhu Y; Zhang XF; Liu DF; Wang Y; Yang C; Shi GD; Peng YP; Zhang K; Tian L; Miao Y; Jiang KR
Cancer Lett; 2017 Nov; 408():144-154. PubMed ID: 28867247
[TBL] [Abstract][Full Text] [Related]
40. HDAC class I inhibitor domatinostat sensitizes pancreatic cancer to chemotherapy by targeting cancer stem cell compartment via FOXM1 modulation.
Roca MS; Moccia T; Iannelli F; Testa C; Vitagliano C; Minopoli M; Camerlingo R; De Riso G; De Cecio R; Bruzzese F; Conte M; Altucci L; Di Gennaro E; Avallone A; Leone A; Budillon A
J Exp Clin Cancer Res; 2022 Mar; 41(1):83. PubMed ID: 35241126
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
